Role of T Cells from Adaptive Immune Responses to Therapies

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 3335

Special Issue Editors


E-Mail Website
Guest Editor
1. Medical Research Core Facility and Platforms, King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh 11481, Saudi Arabia
2. King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
Interests: innate immunity in hypertension; atherosclerosis; hypertension; vascular biology; metabolic/nutritional physiology; diabetes; obesity; cell biology; inflammation; oxidative stress; T cells

E-Mail Website
Guest Editor
1. Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
2. Translational & Clinical Research Institute, The Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
Interests: T cells; anti-microbial immunity; immune memory; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are frequently exposed to external microorganisms and pathogens such as viruses, fungi, and bacteria. Innate and adaptive immune responses are our vital defense system. T cells are the backbone of our adaptive immune system. From bone marrow to the thymus, T cells complete their development and differentiation process before entering the blood to be carried throughout the whole body's circulation and lymphoid tissues. T cells are sensitive to specific antigens presented by cells during infection. T cells are a major population of the adaptive immune system. During immune responses, T cells play a crucial role in identifying external microorganisms such as bacteria and viruses that can cause disease as well as helping B cells to eliminate pathogens. Depending on their specific phenotype, T cells and their subtypes modulate immune responses in inflammatory and autoimmune diseases. Such function highlights the importance of T cells to be used for therapy. Using the adoptive transfer of T cells and their subpopulations becomes innovative as a treatment for different immune or inflammatory diseases. This Special Issue is an Open Access forum for collecting specific and original scientific studies and review articles targeting the enrichment of knowledge in the area of T cell responses and function during infection, inflammatory and autoimmune disease progress. We aim to prepare a solid resource of innovative research articles on the role of T cells in adoptive immunity and therapeutic fields.  Suggested potential topics may be: new T cell variants/functions; the role of T cells in new diseases; immunotherapy; CAR T cells; the adoptive transfer of T cells and subtypes; and proteomic characteristics of T cells during inflammation or immune responses.

Dr. Tilili Barhoumi
Prof. Dr. Stephen Todryk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • T cells
  • inflammation
  • immune system
  • CAR T cells
  • immunotherapy
  • adaptive transfer
  • cell therapy
  • immune checkpoint inhibitors

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 939 KiB  
Review
Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence
by Agata Czaplicka, Mieszko Lachota, Leszek Pączek, Radosław Zagożdżon and Beata Kaleta
Cells 2024, 13(1), 101; https://doi.org/10.3390/cells13010101 - 04 Jan 2024
Cited by 1 | Viewed by 1696
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of malignant and non-malignant disorders. CARs are synthetic transmembrane receptors expressed on genetically modified immune effector cells, including T cells, natural killer (NK) cells, or macrophages, which are able to recognize specific surface [...] Read more.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of malignant and non-malignant disorders. CARs are synthetic transmembrane receptors expressed on genetically modified immune effector cells, including T cells, natural killer (NK) cells, or macrophages, which are able to recognize specific surface antigens on target cells and eliminate them. CAR-modified immune cells mediate cytotoxic antitumor effects via numerous mechanisms, including the perforin and granzyme pathway, Fas and Fas Ligand (FasL) pathway, and cytokine secretion. High hopes are associated with the prospective use of the CAR-T strategy against solid cancers, especially the ones resistant to standard oncological therapies, such as pancreatic cancer (PC). Herein, we summarize the current pre-clinical and clinical studies evaluating potential tumor-associated antigens (TAA), CAR-T cell toxicities, and their efficacy in PC. Full article
(This article belongs to the Special Issue Role of T Cells from Adaptive Immune Responses to Therapies)
Show Figures

Figure 1

13 pages, 2278 KiB  
Review
Maladaptive T-Cell Metabolic Fitness in Autoimmune Diseases
by Irene Rose Antony, Brandon Han Siang Wong, Dermot Kelleher and Navin Kumar Verma
Cells 2023, 12(21), 2541; https://doi.org/10.3390/cells12212541 - 29 Oct 2023
Viewed by 1179
Abstract
Immune surveillance and adaptive immune responses, involving continuously circulating and tissue-resident T-lymphocytes, provide host defense against infectious agents and possible malignant transformation while avoiding autoimmune tissue damage. Activation, migration, and deployment of T-cells to affected tissue sites are crucial for mounting an adaptive [...] Read more.
Immune surveillance and adaptive immune responses, involving continuously circulating and tissue-resident T-lymphocytes, provide host defense against infectious agents and possible malignant transformation while avoiding autoimmune tissue damage. Activation, migration, and deployment of T-cells to affected tissue sites are crucial for mounting an adaptive immune response. An effective adaptive immune defense depends on the ability of T-cells to dynamically reprogram their metabolic requirements in response to environmental cues. Inability of the T-cells to adapt to specific metabolic demands may skew cells to become either hyporesponsive (creating immunocompromised conditions) or hyperactive (causing autoimmune tissue destruction). Here, we review maladaptive T-cell metabolic fitness that can cause autoimmune diseases and discuss how T-cell metabolic programs can potentially be modulated to achieve therapeutic benefits. Full article
(This article belongs to the Special Issue Role of T Cells from Adaptive Immune Responses to Therapies)
Show Figures

Figure 1

Back to TopTop